The current status of clinical PET imaging

Brain and Language

Volumn 51, Issue 9, 1996, Pages 603-613

  Cook, G J R ^a,b   Maisey, M N ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CARDIOLOGY; CLINICAL MEDICINE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; HUMAN; NEUROPSYCHIATRY; ONCOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 22644432617     PISSN: 0093934X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9260(96)80052-3     Document Type: Review

References (108)

1. Huitink JM, Visser FC, van Lingen et al. Feasibility of planar fluorine-18-FDG imaging after recent MI to assess myocardial viability. Journal of Nuclear Medicine 1995;36:975-981.
2. Macfarlane DJ, Cotton L, Ackerman RJ et al. Triple head SPECT with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET. Radiology 1995;194:425-429.
3. Andersson JL, Sundin A, Valind S. A method of coregistration of PET and MR brain images. Journal of Nuclear Medicine 1995;36:1307-1315.
4. Dahlbom M, Hoffman EJ, Hoh CK et al. Whole body positron emission tomography: Part 1. Method and performance characteristics. Journal of Nuclear Medicine 1992;33:1191-1199.
5. Hanson MW, Glantz MJ, Hoffman JM et al. FDG-PET in the selection of brain lesions for biopsy. Journal of Computer Assisted Tomography 1991;15:796-801.
6. Leskinen-Kallio S, Ruotsalainen U, Nagren K et al. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkins lymphoma: a PET study. Journal of Nuclear Medicine 1991; 32:1211-1218.
7. Newman JS, Francis IR, Kaminski MS et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111-116.
8. Okada J, Oonishi H, Yoshikawa et al. FDG PET for predicting the prognosis of malignant lymphoma. Annals of Nuclear Medicine 1994;8:187-191.
9. Gupta NC, Frank AL, Dewan N et al. Solitary pulmonary nodules: detection of malignancy with PET 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-444.
10. Kubota K, Matsuzawa T, Fujiwara T et al. Differential diagnosis of lung tumour with positron emission tomography: a prospective study. Journal of Nuclear Medicine 1990;31:1927-1932.
11. Patz PP, Lowe VJ, Hoffman JM et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-490.
12. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-1266.
13. Strauss LG, Conti, PS. The applications of PET in clinical oncology. Journal of Nuclear Medicine 1991;32:623-648.
14. Coveney EC, Geraghty JG, O'Laoide R et al. Reasons underlying negative mammography in patients with palpable breast cancer. Clinical Radiology 1994;49:123-125.
15. Kaufman Z, Shpitz B, Shapiro M et al. Triple approach in the diagnosis of dominant breast masses: combined physical examination, mammography, and fine needle aspiration. Journal of Surgical Oncology 1994;56:254-257.
16. Crowe JP, Adler LP, Shenk R et al. Positron emission tomography and breast masses: comparison with clinical, mammographic and pathological findings. Annals of Surgical Oncology 1994;1:1132-1140.
17. Tse NY, Hoh CK, Hawkins RA et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Annals of Surgery 1992;216:27-34.
18. Adler LP, Crowe JP, al-Kaisi NK et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187:743-750.
19. Wahl RL, Helvie MA, Chang AE et al. Detection of breast cancer in women after augmentation mammoplasties using fluorine-18-fluorodeoxyglucose-PET. Journal of Nuclear Medicine 1994;35:872-875.
20. Wahl RL, Cody RL, Hutchins GD et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
21. Jansson T, Westlin JE, Ahlstrom H et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? Journal of Clinical Oncology 1995;13:1470-1477.
22. Leskinen-Kallio S, Nagren K, Lehikoinen P et al. Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. British Journal of Cancer 1991; 64:1121-1124.
23. Nieweg OE, Kim EE, Wong WH et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-3925.
24. Thyagarajan D, Cascino T, Harms G. Magnetic resonance imaging in brachial plexopathy of cancer. Neurology 1995;45: 421-427.
25. Wahl RL, Zasadny K, Helvie M et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. Journal of Clinical Oncology 1993;11:2101-2111.
26. Huovinen R, Leskinen-Kallio S, Nagren K et al. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. British Journal of Cancer 1993;67:787-791.
27. Lindholm P, Leskinen-Kallio S, Minn H et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. Journal of Nuclear Medicine 1993;34:1711-1716.
28. Leskinen-Kallio S, Nagren K, Lehikoinen P et al. Carbon-11-methionine and PET is an effective method to image head and neck cancer. Journal of Nuclear Medicine 1992;33:691-695.
29. Rege S, Maass A, Chaiken L et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;74:3047-3058.
30. Bailet JW, Abemayor E, Jabour BA et al. Positron emission tomography: a new, precise imaging modality for dectection of primary head and neck tumours and assessment of cervical lymphadenopathy. Laryngoscope 1992;102:281-288.
31. McGuirt WF, Williams DW, Keyes JW et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995;105:373-375.
32. Braams JW, Pruim J, Frelinng NJ et al. Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI. Journal of Nuclear Medicine 1995;36:211-216.
33. Berlangieri SU, Brizel DM, Scher RL et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head and Neck 1994;16:340-346.
34. Greven KM, Williams DW, Keyes JW et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994;74:1355-1359.
35. Haberkorn U, Strauss LG, Dimitrakopolou A et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. Journal of Nuclear Medicine 1993;34:12-17.
36. Zeitouni AG, Yamamoto YL, Black M et al. Functional imaging of head and neck tumours using positron emission tomography. Journal of Otolaryngology 1994;23:77-80.
37. Grabbe E, Winkler R. Local recurrence after sphincter-saving resection for rectal and rectosigmoid carcinoma: value of diagnostic methods. Radiology 1985;155:305-310.
38. Gupta NC, Falk PM, Frank AL et al. Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebraska Medical Journal 1993;78:30-35.
39. Strauss LG, Clorius JH, Schlag P et al. Recurrence of colorectal tumours: PET evaluation. Radiology 1989;170:329-332.
40. Steinert HC, Huch Boni RA, Buck A et al. Malignant melanoma: staging with whole body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-709.
41. Gritters LS, Francis IR, Zasadny KR et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of melanoma. Journal of Nuclear Medicine 1993;34:1420-1427.
42. Di Chiro G, DeLaPaz RL, Brooks RA et al. Glucose utilization of cerebral gliomas measured by 18F fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-1329.
43. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Investigative Radiology 1987;22:360-371.
44. Alavi JB, Alavi A, Chawluk J et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988; 62:1074-1078.
45. Ogawa T, Kanno I, Shishido F. Clinical value of PET with 18F fluorodeoxyglucose and L methyl-11C-methionine for the diagnosis of recurrent brain tumour and radiation injury. Acta Radiologica 1991;32:197-202.
46. Kubota R, Kubota K, Yamada S et al. Methionine uptake by tumour tissue: A microautoradiographic comparison with FDG. Journal of Nuclear Medicine 1995;36:484-492.
47. Ogawa T, Shishudo F, Kanno I. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45-53.
48. Hutchins GD, Schwaiger M, Rosenspire KC et al. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. Journal of the American College of Cardiologists 1990;15:1032-1042.
49. Gould KL. Positron emission tomography and interventional cardiology. American Journal of Cardiology 1990;66:51F-58F.
50. Demer L, Gould K, Goldstein R et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation 1989;79:825-835.
51. Schelbert H, Wisenberg G, Phelps M et al. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic vasodilatation: VI: Detection of coronary artery disease in man with intravenous N-13 ammonia and positron computed tomography. American Journal of Cardiology 1982;49:1197-1207.
52. Go RT, Marwick TH, MacIntyre WJ et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. Journal of Nuclear Medicine 1990;31:1899-1905.
53. Stewart R, Schwaiger M, Molina E et al. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. American Journal of Cardiology 1991;67:1303-1310.
54. Mody FV, Brunken RC, Stevenson LW et al. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron emission tomography. Journal of the American College of Cardiologists 1991;17:373-383.
55. Di Carli MF, Davidson M, Little R et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. American Journal of Cardiology 1994;73:527-533.
56. Tamaki N, Kawamoto M, Takahashi N et al. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: comparison with stress thallium imaging. Journal of the American College of Cardiology 1993;22:1621-1627.
57. Knuuti MJ, Saraste M, Nuutila P et al. Myocardial vaibility: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. American Heart Journal 1994;127:785-796.
58. Schelbert HR, Schwaiger M. Positron emission tomography in human myocardial ischaemia. Herz 1987;12:22-40.
59. Liu P, Kiess M, Okada R et al. The persistent defect on exercise thallium imaging and its fate after myocardial revascularization: does it represent scar or ischaemia? American Heart Journal 1985;110:996-1001.
60. Dilsizian V, Rocco T, Freeman N et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. New England Journal of Medicine 1990;323:141-146.
61. Brown M, Marshall D, Sobel B et al. Assessment of myocardial oxidative capacity with radiolabeled acetate. Circulation 1986;74:513.
62. Brunken R, Tillisch J, Schwaiger M et al. Regional perfusion, glucose metabolism, and wall motion in patients with chronic electrocardiographic Q-wave infarctions: evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation 1986;73:951-963.
63. Berry JJ, Hoffman JM, Steenbergen C et al. Human pathologic correlation with PET in ischemic and non ischemic cardiomyopathy. Journal of Nuclear Medicine 1993;34:39-47.
64. Tillisch J, Brunken R, Marshall R et al. Reversibility of cardiac wall motion abnormalities predicted by positron emission tomography. New England Journal of Medicine 1986;314:884-888.
65. Schwaiger M, Kalff V, Rosenspire K et al. The noninvasive evaluation of the sympathetic nervous system in the human heart by PET. Circulation 1990;82:457-464.
66. Shelton ME, Dence CS, Hwang DR et al. Myocardial kinetics of flourine-18 misonidazole: a marker of hypoxic myocardium. Journal of Nuclear Medicine 1989;30:351-358.
67. Engel J, Henry TR, Risinger MW et al. Presurgical evaluation of partial epilepsy: relative contributions of depth electrode recordings versus FDG PET and scalp-sphenoidal ictal EEG. Neurology 1990;40:1670-1677.
68. Engel J, Kuhl DE, Phelps ME et al. Interictal cerebral glucose metabolism in partial epilepsy and its relation to EEG changes. Annals of Neurology 1982;12:510-517.
69. Chugani HT, Rintahaka PJ, Shewmon DA. Ictal patterns of cerebral glucose utilization in children with epilepsy. Epilepsia 1994;35:813-822.
70. 99mTc HMPAO SPECT. Annals of Neurology 1992;31:650-656.
71. Ho SS, Berkovic SF, Berlangieri SU et al. Comparison of ictal SPECT and interictal PET in the presurgical evaluation of temporal lobe epilepsy. Annals of Neurology 1995;37:738-745.
72. Gaillard WD, Bhatia S, Bookheimer SY et al. FDG PET and volumetric MRI in the evaluation of patients with partial epilepsy. Neurology 1995;45:123-126.
73. Stefan H, Pawlik G, Bocher-Schwarz HG et al. Functional and morphological abnormalities in temporal lobe epilepsy: a comparison of interictal and ictal EEG, CT, MRI, SPECT and PET. Journal of Neurology 1987;234:377-384.
74. Manno EM, Sperling MR, Ding X et al. Predictors of outcome after anterior temporal lobectomy: positron emission tomography. Neurology 1994;44:2331-2336.
75. Heinz R, Ferris N, Lee EK et al. MR and positron emission tomography in the diagnosis of surgically correctable temporal lobe epilepsy. American Journal of Neuroradiology 1994;15:1341-1348.
76. Burdette DE, Sakurai SY, Henry TR et al. Temporal lobe central benzodiazepine binding in unilateral mesial temporal lobe epilepsy. Neurology 1995;45:934-941.
77. Savic I, Ingvar M, Stone-Elander S. Comparison of [11C] flumazenil and [18] FDG as PET markers of epileptic foci. Journal of Neurology, Neurosurgery and Psychiatry 1993;56:615-621.
78. Savic I, Widen E, Thorell JO et al. Cortical benzodiazepine receptor binding in patients with generalised and partial epilepsy. Epilepsia 1990;31:724-730.
79. Chugani HT, Shields WD, Shewmon DA et al. Infantile spasms. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment. Annals of Neurology 1990;27:406-413.
80. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34:934-944.
81. Duara R, Grady C, Haxby J et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879-887.
82. Haxby JV, Grady CL, Duara R et al. Neocortical metabolic abnormalities precede non memory cognitive defects in early Alzheimer's-type dementia. Archives of Neurology 1986;43:882-885.
83. Chawluk JB, Alavi A, Dann R et al. Positron emission in aging and dementia: effect of cerebral atrophy. Journal of Nuclear Medicine 1987;28:431-437.
84. Kuhl DE, Small GW, Riege WH et al. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease. Journal of Cerebral blood Flow and Metabolism 1987;7:S406.
85. Mielke R, Pietrzyk U, Jacobs A et al. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: a comparison of perfusion and metabolic pattern. European Journal of Nuclear Medicine 1994;21:1052-1060.
86. Kumar A, Schapiro MB, Grady C et al. High resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 1991;4: 35-46.
87. Heiss WD, Szelies B, Kessler J et al. Abnormalities of energy metabolism in Alzheimer's disease studied with PET. Annals of the New York Academy of Sciences 1991;640:65-71.
88. Guze BH, Baxter ER, Schwartz JM et al. Changes in glucose metabolism in dementia of the Alzheimer type compared with depression: a preliminary report. Psychiatry Research 1991;40: 195-202.
89. Kessler J, Herholz K, Grond M et al. Impaired metabolic activation in Alzheimer's disease: a PET study during continuous visual recognition. Neuropsychologia 1991;29:229-243.
90. Duara R, Gutterman A, Loewenstein D et al. The clinical and PET scan pattern of probable Pick's disease. Neurology 1988;38:415.
91. Karbe H, Holthoff V, Huber M et al. Positron emission tomography in degenerative disorders of the dopaminergic system. Journal of Neural Transmission 1992;4:121-130.
92. Kuhl DE, Phelps ME, Markham CH et al. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Annals of Neurology 1982;12:425-434.
93. Mazziotta JC, Phelps ME, Pahl JJ et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. New England Journal of Medicine 1987;316:357-362.
94. Hoffman JM, Waskin HA, Schifter T et al. FDG PET in differentiating lymphoma from non malignant CNS lesions in patients with AIDS. Journal of Nuclear Medicine 1993;34:567-575.
95. Brunetti A, Berg G, Di Chiro G et al. Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3′-azido2′-didoxythymidine (AZT, zidovudine): a PET-FDG study. Journal of Nuclear Medicine 1989;30:581-590.
96. Wong DF, Wagner HN, Tune LE et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-1563.
97. Perani D, Colombo C, Bressi S et al. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. British Journal of Psychiatry 1995;166: 244-250.
98. Buchsbaum MS, Wu J, DeLisi LE et al. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. Journal of Affective Disorders 1986;10:137-152.
99. Stoppe G, Wildhagen K, Seidel JW et al. Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 1990;40:304-308.
100. Stoppe G, Wildhagen K, Meyer GJ et al. Use of fluorodeoxyglucose PET in the diagnosis of central nervous system systemic lupus erythematosus and a comparison with CT and MRI. Nuklearmedizin 1989;28:187-192.
101. Jones T, Chesler DA, Ter-Pogossian MM. The continuous inhalation of oxygen-15 for assessing regional oxygen extraction in the brain of man. British Journal of Radiology 1976;49:399-343.
102. Hakim AM, Pokrupa RP, Villanueva J et al. The effect of spontaneous reperfusion on metabolic function in early human cerebral infarct. Annals of Neurology 1987;21:279-289.
103. Wise R, Bernadi S, Frackowiak R et al. Serial observations on the pathophysiology of acute stroke: the transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain 1983;106:197-222.
104. Heiss WD, Huber M, Fink GR et al. Progressive derangement of periinfarct viable tissue in ischaemic stroke. Journal of Cerebral Blood Flow and Metabolism 1992;12:193-203.
105. Baron J, Rougemont D, Bousser M et al. Local interrelationships of cerebral oxygen consumption and glucose utilisation in normal subjects and in ischaemic stroke patients. Journal of Cerebral Blood Flow and Metabolism 1984;4:140-149.
106. Heiss WD, Holthoff V, Pawlik G et al. Effect of nimodipine on regional cerebral glucose metabolism in patients with acute ischaemic stroke as measured by positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 1990;10:127-132.
107. Hakim AM, Evans AC, Berger L et al. The effect of nimodipine on the evolution of human cerebral infarction studied by PET. Journal of Cerebral Blood Flow and Metabolism 1989;9:523-534.
108. De Ley G, Weyne J, Demeester G et al. Experimental thromboembolic stroke studied by positron emission tomography: immediate versus delayed reperfusion by fibrinolysis. Journal of Cerebral Blood Flow and Metabolism 1988;8:539-545.